This article reports the clinical trial (phase III) conducted on total 1620 participants to assess the effect of FF/VI 100/25 µg on lung function in COPD. The drug combination was compared against VI 25 µg alone for 14 weeks. Study Background Globally, chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity. Of these 30 million COPD patients reside in India and the number is increasing rapidly every year.
It is found that the inhaled corticosteroids (ICS)/long-acting b2-antagonist (LABA) combination therapy is more effective than monotherapy in improving lung function, reducing the exacerbations events, and improving the quality of life in COPD patients. Many Indian pulmonologists suggest on the use of ICS/LABA combination. The currently approved regimen includes the combination of fluticasone furoate (FF)/vilanterol (VI) as a once-daily treatment for…
